Eledon Pharmaceuticals, Inc. (ELDN) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Eledon Pharmaceuticals reported revenue of $0. Net income was -$45.6M, or -$0.52 per diluted share. Operating activities generated -$62.3M of cash. At fiscal year end, Eledon Pharmaceuticals held $169.0M in total assets against $32.2M in total liabilities, including $22.8M of cash and equivalents.
Open the full interactive Eledon Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Eledon Pharmaceuticals Key Stats
| Share Price | $2.34 |
|---|---|
| Market Cap | $265.9M |
| 52-Week Range | $1.39 – $4.36 |
| Shares Outstanding | 113.6 million (basic, 2026 Q2) |
Eledon Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$18.5M | -$36.9M | -$88.4M | -$43.0M | -$70.6M | — |
| Pre-Tax Income | -$23.2M | -$36.9M | -$88.0M | -$40.3M | -$35.8M | -$45.6M |
| Income Tax | -$404,000 | -$2.4M | $0 | $0 | $431,000 | $35,000 |
| Net Income | -$22.8M | -$34.5M | -$88.0M | -$40.3M | -$36.2M | -$45.6M |
| Diluted EPS | -$15.72 | -$2.33 | -$6.16 | -$1.64 | -$0.75 | -$0.52 |
Eledon Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$17.5M | -$10.4M | -$39.0M | -$31.6M |
| Diluted EPS | -$0.21 | -$0.13 | -$0.33 | -$0.27 |
Eledon Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $114.2M | $84.8M | $56.4M | $4.6M | $20.5M | $22.8M |
| Current Assets | $115.6M | $88.3M | $59.5M | $56.1M | $143.7M | $135.7M |
| Total Assets | $197.2M | $170.5M | $92.8M | $89.1M | $177.4M | $169.0M |
| Current Liabilities | $2.5M | $4.4M | $6.5M | $3.9M | $11.6M | $18.3M |
| Total Liabilities | $6.6M | $6.6M | $8.6M | $5.6M | $59.3M | $32.2M |
| Shareholders' Equity | $190.6M | $164.0M | $84.2M | $83.4M | $118.1M | $81.1M |
Eledon Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$15.2M | -$28.9M | -$28.4M | -$39.5M | -$47.3M | -$62.3M |
| Cash From Investing | $11.0M | — | — | -$45.3M | -$70.3M | $10.8M |
| Cash From Financing | $109.6M | -$449,000 | — | $33.0M | $133.5M | $53.8M |
| Free Cash Flow | — | -$28.9M | — | — | — | — |
Figures from Eledon Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Eledon Pharmaceuticals financials page for every line item.
Eledon Pharmaceuticals Company Profile
| Ticker | ELDN |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Irvine, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001404281 |
Frequently Asked Questions
What was Eledon Pharmaceuticals' revenue in fiscal 2025?
Eledon Pharmaceuticals (ELDN) reported revenue of $0 for fiscal 2025.
What is Eledon Pharmaceuticals' annual revenue history?
Eledon Pharmaceuticals' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Eledon Pharmaceuticals' net income in fiscal 2025?
Eledon Pharmaceuticals reported net income of -$45.6M for fiscal 2025.
What was Eledon Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Eledon Pharmaceuticals' diluted EPS was -$0.52 for fiscal 2025 (adjusted for any later stock splits).
What was Eledon Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Eledon Pharmaceuticals reported revenue of $0.
How many shares of Eledon Pharmaceuticals are outstanding?
Eledon Pharmaceuticals reported a weighted average of 113.6 million basic shares outstanding in 2026 Q2.
What is Eledon Pharmaceuticals' market cap?
Based on its latest closing price, Eledon Pharmaceuticals (ELDN) has a market capitalization of about $265.9M.
When does Eledon Pharmaceuticals' fiscal year end?
Eledon Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Eledon Pharmaceuticals headquartered?
Eledon Pharmaceuticals lists its business address in Irvine, California in its SEC filings.